Ligand Pharmaceuticals Incorporated (LGND)

Over the past six months, Ligand Pharmaceuticals' stock has experienced significant movement. In August 2025, the company reported strong second-quarter financial results and raised its full-year 2025 revenue guidance. In November 2025, Ligand announced its third-quarter earnings, significantly beating consensus estimates. Following strong financial results, several investment analysts increased their price targets for LGND and reiterated "Buy" or "Outperform" ratings. Over the past three months, Ligand Pharmaceuticals insiders have sold more company stock than they have bought. The stock price has seen significant appreciation, with a 48.74% increase over the past six months and a 73.91% increase over the past year as of January 13, 2026. In September 2025, Ligand entered a co-development agreement with Sequel Med Tech. In August 2025, the company invested US$40 million in Orchestra BioMed Holdings. In July 2025, its subsidiaries merged with Pelthos Therapeutics Inc.

Information directly detailing the demand seasonality for Ligand Pharmaceuticals' products and services is not explicitly available. Based on historical stock performance, buying Ligand Pharmaceuticals Inc (LGND) stock in June has the highest probability of a positive return, while May has the lowest probability. Stock seasonality does not directly equate to demand seasonality for the company's underlying products and services, which are primarily royalty streams from pharmaceutical products and technology licensing.

Ligand Pharmaceuticals, Inc. is an American biopharmaceutical company focused on acquiring, developing, and out-licensing proprietary technologies to help pharmaceutical and biotechnology companies discover and develop novel medicines. The company operates primarily through its research services and royalty-generating businesses, building a diversified portfolio of technology platforms and partnering with industry leaders. Ligand's product offerings center around core platforms like Captisol, OmniAb, and ADME testing services. As of 2024, Ligand's portfolio included royalty rights to approximately 90 pharmaceutical products across various therapeutic areas, including treatments for multiple myeloma, kidney disease, and pneumococcal vaccine.

Headquartered in Jupiter, Florida, Ligand Pharmaceuticals has a global footprint spanning North America, Europe, and Asia. The company operates active Drug Master Files (DMFs) in Japan, China, Canada, and the United States, and its commercial programs are marketed in over 70 countries.

Ligand Pharmaceuticals generally maintains a positive brand reputation within the financial and biotechnology communities, largely due to its successful royalty aggregator model and strong financial performance. The company consistently receives "Moderate Buy" or "Buy" ratings from analysts, with a consensus price target indicating potential upside. The significant institutional ownership signals high conviction from major market players. Recent strong revenue growth and earnings beats contribute positively to its reputation. There has been significant insider selling over the past three months, which may attract shareholder attention.

Ligand Pharmaceuticals Incorporated is overwhelmingly owned by institutional investors, who hold approximately 91.28% of the company's shares. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Individual insiders hold a smaller percentage of the stock, around 1.94% to 7.00%. Bvf Partners L P is noted as a significant individual shareholder, owning 63.33 million shares.